TJ-032(TJ-032) - 在研适应症：肿瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用机制-

治疗领域

肿瘤

在研适应症

肿瘤

非在研适应症-

原研机构

上海拓界生物医药科技有限公司

在研机构

上海拓界生物医药科技有限公司

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

关联

100 项与 TJ-032 相关的临床结果

登录后查看更多信息

100 项与 TJ-032 相关的转化医学

登录后查看更多信息

100 项与 TJ-032 相关的专利（医药）

登录后查看更多信息

1

项与 TJ-032 相关的文献（医药）

1984-03-01·Hinyokika kiyo. Acta urologica Japonica

[Effects of hachimijiohgan and ninjintoh on fertility in males with sterility].

Article

作者: Namiki, M ; Sonoda, T ; Hayashi, T ; Okuyama, A

The effects of TSUMURA HACHIMIJIOHGAN (TJ-7) and TSUMURA NINJINTOH (TJ-32) on patients with the complaint of male sterility due to both or either oligozoospermia or asthenozoospermia were evaluated in comparison with the effects of clomiphene citrate. TJ-7 was administered in 7.5 g doses three times a day for 4 months to 23 patients with oligozoospermia and 20 patients with asthenozoospermia. Sperm count was improved in 5 of the patients (21%) with oligozoospermia and sperm motility was improved in 10 of the patients (50%) with asthenozoospermia. TJ-32 was administered in 5.1 g doses three times a day for 4 months to 26 patients with oligozoospermia and 20 of the patients with asthenozoospermia. Sperm count was improved in 8 of the patients (31%) with oligozoospermia and sperm motility was improved in 9 of the patients (45%) with asthenozoospermia. Both TJ-7 and TJ-32 were more effective in sperm count and motility than clomiphene citrate. No side effects or abnormal laboratory data including serum LH, FSH, testosterone, estradiol and prolactin were observed in any cases.

100 项与 TJ-032 相关的药物交易

登录后查看更多信息